IVP (IVP)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹146.29, IVP is a small-cap specialty chemicals play with a market cap of just ₹141 Cr. The first thing that catches my eye is the valuation: a P/E of 10.12 and a P/B of 1.13 against a book value of ₹129.02. In the Graham tradition, paying close to tangible book for a company with improving earnings is a reasonable starting point. The Piotroski F-score of 7/9 suggests financial health is strengthening, and promoter holding of 71.32% means my interests are broadly aligned with owners. Sales grew 12.07%, and reported profit jumped 161.90%, giving a remarkably low PEG of 0.12. But I must be careful: one year of explosive profit growth is not proof of an economic moat. ROE of 10.19% and ROCE of 9.99% are acceptable, not exceptional. They tell me this is a decent, ordinary business, not a compounding machine. Debt/equity of 0.69 is manageable, but for a small chemical company I would prefer a stronger balance sheet. The latest quarter shows net profit of ₹5 Cr on sales of ₹145 Cr, which implies a thin net margin; earnings are clearly sensitive to costs and pricing. Specialty chemicals can be cyclical, and the 52-week range of ₹110 to ₹194 reminds me that Mr. Market gets emotional. The 161.90% profit growth may reflect a true turnaround, a low base, or favourable one-off factors. With insufficient data to judge durability, I would not rush in. At 1.13 times book and 10 times earnings, there is some margin of safety, but I need several more quarters of steady cash profits before calling this a high-conviction Buffett-style purchase.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer